References
- 1. Loke J, Malladi R, Moss P, Craddock C. The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience. Br J Haematol. 2020;188(1):129-146. doi:10.1111/bjh.16355
- 2. Horowitz, M., Schreiber, H., Elder, A. et al. Epidemiology and biology of relapse after stem cell transplantation. Bone Marrow Transplant 53, 1379–1389 (2018). https://doi.org/10.1038/s41409-018-0171-z
- 3. Schuurhuis GJ, Heuser M, Freeman S, at el. Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party. Blood. 2018; 131(12): 1275–91. https://doi.org/10.1182/blood-2017-09-801498
- 4. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4): 424–447. doi:10.1182/blood-2016-08-733196
- 5. Khanal, Nabin & Banskota, Shristi & Bhatt, Vijaya. (2020). Novel treatment paradigms in acute myeloid leukemia. Clinical Pharmacology & Therapeutics. 10.1002/cpt.1962.
- 6. Dillon R, Hills R, Freeman S, et al. Molecular MRD status and outcome after transplantation in NPM1-mutated AML. Blood. 2020; 135(9): 680–688. doi:10.1182/blood.2019002959
- 7. Rovira M, Suárez-Lledó M. Short- and Long-Term Controls After HSCT. In: Carreras E, Du-four C, Mohty M, Kröger N, eds. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. Cham (CH): Springer; 2019: 149–153.
- 8. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia., J Clin Oncol, 2003, vol. 21: 4642–4649.
- 9. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009; 15(12): 1628–1633. doi:10.1016/j. bbmt.2009.07.004
- 10. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program. Leukemia. 2003;17(12):2318-2357. doi:10.1038/sj.leu.2403135
- 11. Claire L. Green, Kenneth K. Koo, Robert K. Hills, Alan K. Burnett, David C. Linch, and Rosemary E. Gale Prognostic Significance of CEBPA Mutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of Double CEBPA Mutations and the Interaction With FLT3 and NPM1 Mutations J Clin Oncol.2010; 28: 2739–2747
- 12. Jentzsch M, Schwind S, Bach E, Stasik S, Thiede C, Platzbecker U. Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia. Cancers (Basel). 2019; 11(11): 1625. Published 2019 Oct 23. doi: 10.3390/cancers11111625
- 13. Balsat M, Renneville A, Thomas X, et al. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. J Clin Oncol. 2017; 35(2): 185–193. doi:10.1200/JCO.2016.67.1875
- 14. Kayser S, Benner A, Thiede C, et al. Pretrans-plant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia. Blood Cancer J. 2016; 6(7): e449. Published 2016 Jul 29. doi:10.1038/bcj.2016.46
- 15. Qin YZ, Wang Y, Xu LP, et al. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. J Hematol Oncol. 2017; 10(1): 44. Published 2017 Feb 6. doi:10.1186/s13045-017-0414-2
- 16. Zhu HH, Zhang XH, Qin YZ, et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood. 2013; 121(20): 4056–4062. doi:10.1182/blood-2012-11-468348
- 17. Rücker FG, Agrawal M, Corbacioglu A, et al. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. Blood. 2019; 134(19): 1608–1618. doi:10.1182/blood.2019001425
- 18. Tang FF, Xu LP, Zhang XH, et al. Monitoring of post-transplant CBFB-MYH11 as minimal residual disease, rather than KIT mutations, can predict relapse after allogeneic haematopoietic cell transplantation in adults with inv(16) acute myeloid leukaemia. Br J Haematol. 2018; 180(3): 448–451. doi:10.1111/bjh.14340
- 19. Ommen HB, Schnittger S, Jovanovic JV, et al. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood. 2010; 115(2): 198-205. doi:10.1182/blood-2009-04-212530
- 20. Mannelli F, Ponziani V, Bencini S, et al. CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biologicalfeatures. Haematologica.2017; 102(3): 529–540. doi:10.3324/haematol.2016.151910
- 21. Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol. 2010; 28(16): 2739–2747. doi:10.1200/JCO.2009.26.2501
- 22. Rein LA, Sung AD, Rizzieri DA. New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation. IntJHematolOncol. 2013; 2(1): 10.2217/ijh.13.4. doi:10.2217/ijh.13.4